In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion

doi:10.1016/0014-2999(93)90802-O

European Journal of Pharmacology

Volume 230, Issue 2, 12 January 1993, Pages 195-201

https://doi.org/10.1016/0014-2999(93)90802-O Get rights and content

Abstract

We compared the ability of various dopamine (DA) uptake inhibitors to displace the in vivo striatal [³H]GBR 12783 (1-[2(diphenylmethoxy) ethyl)-4-(3-phenyl-1[³H]-2-propenyl)-piperazine) binding with their stimulant effect on locomotor activity on mice. GBR 12783 (8 mg/kg), GBR 13069 (10 mg/kg), cocaine (20 mg/kg), mazindol (3 mg/kg) or pyrovalerone (2 mg/kg) stimulated locomotion as long as they occupied the DA uptake complex. In contrast, nomifensine (3 mg/kg) did not stimulate locomotion although it completed with [³]GBR 12783 for the occupancy of the DA uptake complex at a significant level (> 50%). Administered at their ED₅₀ doses, GBR 12783, BTCP (N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine, GBR 13069, amineptine and dexamphetamine significantly increased locomotor activity whereas the other inhibitors tested did not. The locomotor response elicited by GBR 12783 (10 mg/kg) was not decreased by desipramine (20 mg/kg) nor by oxaprotiline (10 mg/kg). The increase in locomotion elicited by GBR 12783 was positively correlated with the basal locomotor activity of the mice. The stimulant effect of GBR 12783 was potentiated by SKF 525A and by budipine. Additional pharmacological properties might conceal the relationship between the effects of some DA uptake inhibitors on locomotion, and on in vivo occupancy of DA uptake sites.

References (30)

J.-J. Bonnet et al.
GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo
Eur. J. Pharmacol.
(1986)
J.-J. Bonnet et al.
High-affinity [³H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in then central nervous system
Eur. J. Pharmacol.
(1986)
E. Carboni et al.
Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats
Neuroscience
(1989)
A. Chagraoui et al.
In vivo binding of [³H]GBR 12783, a selective dopamine uptake inhibitor, in mouse striatum
Neurosci. Lett.
(1987)
R. Fonne-Pfister et al.
Xenobiotic and endobiotic inhibitors of cytochrome P450 D11 function, the target of the debrisoquine/sparteine type polymorphism
Biochem. Pharmacol.
(1988)
R.E. Heikkila
Differential effects of several dopamine uptake inhibitors and releasing agents on the locomotor activity in normal and reserpinized mice
Life Sci.
(1981)
R.E. Heikkila et al.
Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake
Eur. J. Pharmacol.
(1984)
S.Z. Langer et al.
The amphetamine paradox in dopaminergic transmission
Trends, Pharmacol. Sci.
(1984)
O.H. Lowry et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951)
M. Poncelet et al.
Psychopharmacological effects of nomifensine enantiomers
Eur. J. Pharmacol.
(1985)

S.B. Ross

The central stimulatory action of inhibitors of the dopamine uptake

Life Sci.

(1979)

R.B. Rothman et al.

Tight binding dopamine reuptake inhibitors as cocaine antagonists, A strategy for drug development

FEBS Lett.

(1989)

J.-M. Vaugeois et al.

Relationship between the effects of dexamphetamine on locomotor and on striatal [³H]GBR 12783 binding in vivo

Eur. J. Pharmacol.

(1990)

J.-M. Vaugeois et al.

In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [³H]GBR 12783

Eur. J. Pharmacol.

(1992)

G.R. Wenger

The role of control activity levels in the reported strain differences to the behavioral effects of drugs in mice

Pharmacol. Biochem. Behav.

(1989)

Cited by (43)

Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys
2008, Pharmacology Biochemistry and Behavior
Although inhibition of dopamine transporters (DAT) and the subsequent increase in dopamine clearly play a role in the effects of psychomotor stimulants, the reinforcing effectiveness of DAT inhibitors varies. Previous studies suggest that pharmacokinetic and pharmacodynamic properties of these drugs account for this variability. The present studies compared the time course and behavioral effects of five phenyltropane analogs of cocaine with high affinity for DAT and varying time courses of action in rhesus monkeys. The rate of drug uptake in putamen was measured using positron emission tomography neuroimaging. The rank order of the time to peak drug uptake was cocaine < RTI-336 < RTI-150 < RTI-113 < RTI-177. Cocaine and all five analogs fully substituted for the cocaine cue in animals trained to discriminate cocaine from saline. All of the drugs were self-administered under a progressive-ratio schedule of drug self-administration and reinstated previously extinguished self-administration maintained under a second-order schedule. The time to peak drug uptake corresponded closely with the time to peak discriminative stimulus effects, and there was a trend for the time of peak drug uptake to correspond negatively with the peak number of drug infusions. Collectively, these results indicate that the rate of drug entry in brain can play an important role in the behavioral pharmacology of psychomotor stimulants.
Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys
2007, Pharmacology Biochemistry and Behavior
Although the behavioral-stimulant and reinforcing effects of cocaine and related psychomotor stimulants have been attributed to their actions at the dopamine transporter (DAT), the reinforcing effectiveness of these compounds varies. The properties that confer these differences are important considerations when developing agonist pharmacotherapies for the treatment of stimulant abuse. The present studies focused on the time course of action and pharmacological specificity of six 3-phenyltropane analogs of cocaine (RTI-112, RTI-126, RTI-150, RTI-171, RTI-177, and RTI-336) by observing their behavioral-stimulant, neurochemical, and reinforcing effects in squirrel monkeys. The faster-onset analogs (RTI-126, RTI-150, and RTI-336), and one of the slower-onset DAT selective analogs (RTI-177 and RTI-171) produced behavioral-stimulant effects, while the slower-onset nonselective analog RTI-112 did not. The time to the peak behavioral-stimulant effect and the peak caudate dopamine levels was strongly correlated, but the area under the curve of the time course of behavioral-stimulant effect and dopamine levels was not correlated. These results suggest that the rate of onset plays a more important role than duration of action in the stimulant effect of these analogs. In addition, the slower-onset nonselective analog (RTI-112) clearly did not exhibit any reinforcing effects while the faster-onset nonselective (RTI-126) and all the DAT-selective analogs showed robust reinforcing effects (RTI-150, and RTI-177) or showed trends towards reinforcing effects (RTI-336 and RTI-171). Hence, there was a general trend for compounds that had a faster onset and/or DAT selectivity to produce significant behavioral-stimulant and reinforcing effects.
2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors
2003, Bioorganic and Medicinal Chemistry
There is considerable interest in developing dopamine transporter (DAT) inhibitors as potential therapies for the treatment of cocaine abuse. We report herein our pharmacophore-based discovery and molecular modeling-assisted rational design of 2,3-disubstituted quinuclidines as potent DAT inhibitors with a novel chemical scaffold. Through 3-D-database pharmacophore searching, compound 12 was identified as a very weak DAT inhibitor with K_i values of 7.3 and 8.9 μM in [³H]mazindol binding and in inhibition of dopamine reuptake, respectively. Molecular modeling-assisted rational design and chemical modifications led to identification of potent analogues (−)-29 and 34 with K_i values of 14 and 32 nM for both compounds in binding affinity and inhibition of dopamine reuptake, respectively. Behavioral pharmacological evaluations in rodents showed that 34 has a profile very different from cocaine. While 34 is substantially more potent than cocaine as a DAT inhibitor, it is approximately four times less potent than cocaine in mimicking the discriminative stimulus properties of cocaine in rat. On the other hand, 34 (3–30 mg/kg) lacks either the locomotor stimulant or stereotypic properties of cocaine in mice. Importantly, 34 blocks locomotor stimulant activity induced by 20 mg/kg cocaine in mice, with an estimated ED₅₀ of 19 mg/kg. Taken together, our data suggest that 34 represents a class of potent DAT inhibitors with a novel chemical scaffold and a behavioral pharmacological profile different from that of cocaine in rodents. Thus, 34 may serve as a novel lead compound in the ultimate development of therapeutic entities for cocaine abuse and/or addiction.
Design, synthesis, and characterization of a novel, 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine-based, dopamine transporter photoaffinity label
2001, Life Sciences
The dopamine transporter (DAT) has been implicated strongly in cocaine's reinforcing effects. Many derivatives of piperidine analogs of GBR 12909 have been developed and were found to be quite potent and selective for the DAT. In this regard, most of these derivatives were found to be much more selective for the DAT than conventional GBR compounds e.g. GBR 12909 when their selectivity was compared with the serotonin transporter (SERT). A brief structure-activity relationship (SAR) study has been carried out in the development of a novel photoaffinity ligand which illustrated the effect of the presence of a sterically bulky iodine atom next to the azido group in activity and selectivity for the DAT. This SAR study also led to the development of the compound 4 which is one of the most potent and selective blockers for the DAT known today. The photoaffinity ligand [¹²⁵I]AD-96-129 was incorporated into the DAT molecule as was demonstrated by immunoprecipitation with serum 16 which is specific for DAT. This photolabeling was antagonized by DAT-specific blockers and was unaffected by specific SERT and norepinephrine transporter (NET) blockers indicating interaction of this novel ligand with the DAT.
SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: Evidence for a functional 'atypical' adenosine A(2A) receptor
2000, European Journal of Pharmacology
The acute motor effects elicited by drugs acting upon adenosine A_2A receptors, namely the highly selective agonist CGS 21680 or the antagonists SCH 58261 and ZM 241385, were investigated in mice. CGS 21680 dose-dependently (0.1–2.5 mg/kg i.p.) decreased horizontal and vertical motor activities. The depressant effect of CGS 21680 (0.5 mg/kg i.p.) was maintained in mice pretreated by the adenosine receptor antagonist 8-(p-sulfophenyl)-theophylline (10–30 mg/kg i.p.), which poorly penetrates the blood–brain barrier, but was completely lost in adenosine A_2A receptor knockout mice. Thus, the adenosine A_2A receptor is critically involved in motor activity. SCH 58261 (1–10 mg/kg i.p.) increased locomotion and rearing with a quick onset, but for a shorter period in mice habituated to the environment than in mice unfamiliar to it. ZM 241385 (7.5–60 mg/kg i.p.) stimulated horizontal and vertical activities with a slow onset at the two highest tested doses, similarly in naive and in habituated mice. The increase in locomotion elicited by ZM 241385 (15–30 mg/kg i.p. and 10–20 nM i.c.v.) was retained in mice treated by CGS 21680 (0.5 mg/kg i.p.) but that elicited by SCH 58261 (1–3–10 mg/kg i.p. and 10–20 nM i.c.v.) partially subsided. In conclusion, both ‘striatal-like’/‘SCH 58261-sensitive’ adenosine A_2A receptors and ‘ZM 241385-sensitive’/‘atypical’ CGS 21680 binding sites may mediate CGS 21680-induced motor effects. Moreover, our results suggest that ‘atypical’ CGS 21680 binding sites could be adenosine A_2A receptors with a peculiar pharmacological profile.
Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor
1999, Pharmacology Biochemistry and Behavior
We investigated whether the antidepressant tianeptine shares the dopamine uptake inhibitory properties of the chemically related antidepressant amineptine. Tianeptine dose dependently (5, 10, 20, 40 mg/kg IP) increased locomotor activity in mice. This stimulant effect (20 mg/kg IP) was dose dependently prevented not only by the D₁ dopamine receptor antagonist SCH 23390 (7.5, 15, 30 μg/kg SC), but also by the D₂ dopamine receptor antagonist haloperidol (50, 100, 200 μg/kg IP), in contrast to that elicited by dopamine uptake inhibitors. Where the latter prevent dexamphetamine-induced (3 mg/kg SC) reversion of akinesia in mice pretreated with reserpine (4 mg/kg SC, 5 h before test), tianeptine (20 mg/kg IP, 30 min before test) did not. Tested up to a concentration of 10−4 M, tianeptine did neither inhibit the [³H]dopamine uptake into mouse striatal synaptosomes nor compete in vitro with the specific binding of [³H]WIN 35,428 at dopamine transporters from striatal membranes. Finally, in mice injected IV with a tracer dose of [³H]WIN 35,428 (1 μCi), the highest tested dose of tianeptine (40 mg/kg IP) did not reduce the specific binding of the radioligand to striatal dopamine transporters. It is concluded that the antidepressant effect of tianeptine does not depend upon a blockade of the neuronal dopamine transporter.

View all citing articles on Scopus

View full text

In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion

Abstract

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Neuroscience

Neurosci. Lett.

Biochem. Pharmacol.

Life Sci.

Eur. J. Pharmacol.

Trends, Pharmacol. Sci.

J. Biol. Chem.

Eur. J. Pharmacol.

Life Sci.

FEBS Lett.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Pharmacol. Biochem. Behav.